Srinivasa Nagalla, MD
Dr. Nagalla is the principal founder and chief executive officer of DiabetOmics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of Pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums on biotechnology, genomics, and proteomics. Dr. Nagalla has over 25 years of broad, multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his MD from the All-India Institute of Medical Sciences in New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.
Robert Murtfeldt, MBA
Robert Murtfeldt is a 30+ year veteran in the medtech and biotech industries. He has held executive leadership positions in world-class global healthcare companies – Johnson & Johnson, Medtronic and Baxter Healthcare. He has also been an entrepreneurial leader with a history of forming, financing and developing young healthcare businesses including MiniMed (sold to Medtronic in 2001 for $3.7 Bil), Insulet (public company with $2.5 Bil market cap) and Neocrin (now ViaCyte). He is a seasoned business development professional, experienced in evaluating, negotiating, closing and integrating a variety of transactions including M&A, partnerships and technology licensing. Mr. Murtfeldt holds technical degrees in Chemical Engineering and Biochemistry from the University of Wisconsin, and an MBA in Corporate Finance from the University of Southern California.
Ms. Chiapuzio brings over 20 years of experience growing privately-held entrepreneurial environments in a range of industries including technology, software-as-a-service and manufacturing. Prior to joining Diabetomics, Ms. Chiapuzio served as chief financial officer of Smarsh, a software-as-a-service company providing archiving and compliance solutions, and as chief financial officer of Network Elements, a manufacturer of optical modules. She was vice president of finance at Claremont Technology Group, an IT consulting firm, where she played a leading role in the company’s IPO process. She began her career in public accounting at KPMG. Ms. Chiapuzio holds a BS in Business Administration with a concentration in Accounting from Portland State University.
Paturi V. Rao, MD, PhD, FRCP
Dr. Rao is co-founder and director for DiabetOmics operations in India and Asia. Dr. Rao was previously Professor and Chief of Endocrinology at Nizam’s Institute of Medical Sciences University in Hyderabad, India, and established the Research Society for the Study of Diabetes in India (RSSDI) and served as Secretary from 1993-2007. RSSDI is the largest diabetes care providers’ organization in Asia, with more than 7000 member diabetologists. Dr. Rao has served as principal investigator on several key international clinical studies in diabetes, including ORIGIN, DREAM, and several phase-II and phase-III clinical trials for Novo Nordisk, Eli Lilly, Aventis, Merck Sharp & Dohme, Novartis, and Johnson & Johnson. Dr. Rao serves on the advisory committees of the Indian Council of Medical Research, the Department of Science & Technology, and several pharmaceutical companies.
Charles Roberts, PhD
Dr. Roberts is co-founder and chief science officer since 2008. Dr. Roberts is a molecular endocrinologist with over 30 years of experience in diabetes research, is an internationally recognized expert on insulin action, and has authored over 250 scientific papers and review articles. Dr. Roberts is also a co-inventor on various patents on therapeutics and biomarkers for clinical diagnostics, and serves on numerous review panels for the National Institutes of Health and the editorial boards of several major biomedical research journals. From 1984-1994, he was a Senior Investigator in the Diabetes Branch of the National Institutes of Health, and subsequently Professor and Associate Chair for Research in the Department of Pediatrics and Professor of Medicine at Oregon Health & Science University.
Eric Bean, PhD
Dr. Bean joined DiabetOmics in 2012 and serves as Vice President and Director of Product Development. He has over 20 years of management experience in the biotechnology sector, with an emphasis on immunoassay development and manufacturing. Prior to joining DiabetOmics Dr. Bean was a partner and Executive Vice President and Chief Technical Officer at HTI Bio-Products, where he developed numerous antibody products for the clinical diagnostic market. As Director of Research and Development at Synbiotics Corporation, Dr. Bean was instrumental in the development and commercialization of over fifteen immunoassay products for the human and animal healthcare markets, including some of the first point-of-care devices for hCG, Group A Strep, and Chlamydia.
Emmanuel Mpock, MBA
Mr. Mpock joined DiabetOmics in 2016 as Vice President of Manufacturing Operations. He brings 20+ years of experience in design and development of point-of-care medical diagnostics and has taken multiple products from concept through the FDA and into the global market. He brings expertise in the areas of design and development of manufacturing equipment, medium speed lines to enhance output, and efficiency and reduce production cost for disposable cartridges. Prior to joining diabetomics, Mr. Epock was involved in the development of diagnostic products for J&J (Lifescan), Alere (Hemosense), Abbott Labs and other multinational companies. He is also the inventor for several diagnostics equipment patents.
Steven Kazmierczak, PhD, DABCC
Dr. Kazmierczak joined DiabetOmics in 2010 and serves as the director of CLIA laboratory operations. He has over 20 years of experience in laboratory medicine. He is board-certified in chemical pathology, and has interests in the development, evaluation, and clinical application of diagnostic laboratory test systems. He serves as Director of the Scientific Advisory Board for ABAXIS Corp., Gamma Therapeutics, and Albumetix. Dr. Kazmierczak is also on the editorial board of several journals specializing in laboratory medicine, is Associate Editor of Clinical Chemistry and Laboratory Medicine, and serves on numerous national committees for the AACC, ASCP, and CAP.
Sumeet Roy, BS, MBA, PhD
Dr. Roy is Vice President and Manager of DiabetOmics Medical (P), Ltd. – the Indian manufacturing plant of DiabetOmics, Inc. He brings over 20 years of experience in the healthcare industry. Prior to joining DiabetOmics, Dr. Roy served as the chief executive officer of Kamineni Life Sciences, a leading manufacturer of Invitro Diagnostic Reagents in India. He has extensive experience in clinical research administration and worked for three years in clinical research administration at the Dept. of Psychiatry, University of South Florida in Tampa. He serves as a qualified quality assessor of Clinical Trial Sites, Ethics Committees and Investigators for National Accreditation Board for Hospitals and Healthcare Providers (NABH) in India. Dr. Roy holds a Masters in Business Administration and PhD in Management.
Raghavan brings over 30 years of experience in medical device sales and marketing. Prior to joining Diabetomics, he was General Manager for Corporate Clients and public private partnership projects, at TransAsia Bio-Medicals Ltd., an Indian multinational in lab diagnostics. He has held executive positions at Boehringer Mannheim India Ltd, Nicholas Piramal India Ltd, and QIAGEN for Asia division. Raghavan has worked in key Asian markets of China, Hong Kong, Taiwan, Korea, Malaysia, Singapore, India and Sri Lanka. Raghavan has an MSc in Chemistry and a Certificate program in Senior Management from Indian Institute of Management (IIM) Kolkata.